Papaverine and hepatotoxicity.
Six of 14 patients receiving a sustained release papaverine preparation developed abnormal liver function tests. One patient had jaundice and another abnormal liver histology on a biopsy specimen. This is only the third report of impaired liver function following the administration of papaverine--a drug which has been used in clinical medicine for over 100 years.
D000368:Aged; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D010208:Papaverine / Q000009:adverse effects*
D003692:Delayed-Action Preparations; D010208:Papaverine